| EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans A Van Hoecke, L Schoonaert, R Lemmens, M Timmers, KA Staats, ... Nature medicine 18 (9), 1418-1422, 2012 | 370 | 2012 |
| Identification and characterization of Nanobodies targeting the EphA4 receptor L Schoonaert, L Rue, B Roucourt, M Timmers, S Little, L Chavez-Gutierrez, ... Journal of Biological Chemistry 292 (27), 11452-11465, 2017 | 33 | 2017 |
| Cochlear supporting cell transdifferentiation and integration into hair cell layers by inhibition of ephrin-B2 signalling J Defourny, S Mateo Sánchez, L Schoonaert, W Robberecht, A Davy, ... Nature communications 6 (1), 7017, 2015 | 29 | 2015 |
| Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework–Corrigendum A Whittal, C Jommi, G De Pouvourville, D Taylor, L Annemans, ... International Journal of Technology Assessment in Health Care 38 (1), e43, 2022 | 18* | 2022 |
| Innovative solutions for paradigm changing new therapies–policy report based on multi-stakeholder round tables I Maes, H Boufraioua, L Schoonaert, W Van Dyck Brussels, Belgium: Vlerick Business School and Inovigate, 2019 | 6 | 2019 |
| Towards integrated care in Belgium: stakeholders' view on maturity and avenues for further development. AS Lambert, S Op de Beeck, AL Van Innis, P Vandenbroeck, J De Groote, ... Belgian Healthcare Knowledge Centre (KCE), 2022 | 4 | 2022 |
| Cochlear supporting cell transdifferentiation and integration into hair cell layers by inhibition of ephrin-B2 signalling. Nat. Commun. 6, 7017 J Defourny, S Mateo Sánchez, L Schoonaert, W Robberecht, A Davy, ... | 4 | 2015 |
| Lowering EphA4 does not ameliorate disease in a mouse model for severe spinal muscular atrophy L Poppe, S Smolders, L Rué, M Timmers, A Lenaerts, A Storm, ... Frontiers in Neuroscience 13, 1233, 2019 | 3 | 2019 |
| Access decision-making in the Belgian Commission for reimbursement of medicines 2010-2017: Investigating the readiness for value-based pricing W Van Dyck, L Schoonaert, T Geldof, L Govaerts | 1 | 2018 |
| EE525 Exploring the Implementation of Polygenic Risk Scoring in Alzheimer's Disease: An Early Value Model A Werbrouck, C Verdonck, Y Abakkouy, I Cleynen, R Vandenberghe, ... Value in Health 27 (12), S159, 2024 | | 2024 |
| HPR143 Standardizing Cross-Border Access to Advanced Therapies A Werbrouck, L Schoonaert, T Bols, A Schuil, S Vermeersch Value in Health 26 (12), S278-S279, 2023 | | 2023 |
| Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework (vol 38, E23, 2022) A Whittal, C Jommi, G De Pouvourville, D Taylor, L Annemans, ... INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 38 (1), 2022 | | 2022 |
| Vers des soins (plus) intégrés en Belgique AS Lambert, S Op de Beek, D Herbaux, J Macq, P Rappe, O Schmitz, ... | | 2022 |
| Innovative solutions for paradigm changing new therapies I Maes, H Boufraioua, W Van Dyck, L Schoonaert | | 2019 |
| Acting with foresight in times of budget austerity W Van Dyck, L Schoonaert | | 2019 |
| Flexibel werken in ziekenhuizen: Over werklast, draagkracht en verandercultuur B Cardoen, L Schoonaert, P Gemmel | | 2018 |
| Flexibel werken in ziekenhuizen: OM en HRM perspectief L Schoonaert, P Gemmel, B Cardoen Vlerick Business School, 2018 | | 2018 |
| Impact of uncertainty in times of network formation B Cardoen, C Peeters, W Van Dyck, L Schoonaert Vlerick Business School, 2017 | | 2017 |
| EXPLORING THE MECHANISM EXPLORING THE MECHANISM AND THERAPEUTIC POTENTIAL OF THE EPHRIN SYSTEM IN ALS L Schoonaert | | 2016 |
| Development of a SPE-LC-UV method for analysis of MPB in brain and spinal cord H Chen, Y Xu, L Schoonaert, E Adams, W Robberecht, A Van Schepdael Forum of Pharmaceutical Sciences, Date: 2012/05/07-2012/05/08, Location …, 2012 | | 2012 |
